• Heart disease remains the world's top killer, claiming more lives each year than any other condition.
  • Scientists are uncovering how gut microbes may influence coronary artery disease (CAD), one of the most common and serious forms of heart disease.
  • A research team in Seoul has identified 15 specific bacterial species connected to CAD, offering new insight into how the gut and heart interact.
  • Their analysis reveals several biological pathways tied to disease severity, including heightened inflammation and disruptions in metabolism that may worsen heart health.

Cardiovascular diseases claim nearly 20 million lives each year, making them the leading cause of death worldwide. While genetics and lifestyle factors clearly affect a person's heart health, scientists are discovering that microorganisms living in the gut may also have an important influence. These microbes appear to be deeply involved in the development of coronary artery disease (CAD), though their exact roles have long been unclear.

Recent research suggests that the gut microbiome may promote CAD through a variety of biological pathways, influencing inflammation and metabolism in ways that impact the arteries. However, which specific bacteria are responsible -- and how they contribute to disease progression -- has remained uncertain.

Mapping Microbes in Coronary Artery Disease

Researchers in Seoul are beginning to unravel this mystery. Writing in mSystems, a team led by Han-Na Kim, Ph.D., at the Samsung Advanced Institute for Health Sciences and Technology at Sungkyunkwan University, examined how gut microbes interact with the cardiovascular system. "We've gone beyond identifying 'which bacteria live there' to uncovering what they actually do in the heart-gut connection," Kim explained.

The team analyzed fecal samples from 14 people with CAD and compared them to samples from 28 healthy participants using metagenomic sequencing, a powerful technique that identifies all the DNA within a sample. This approach allowed them to reconstruct the genetic makeup of individual microbes. From this analysis, the researchers identified 15 bacterial species linked to CAD and mapped the pathways that connect these microbes to the severity of the disease.

Inflammation, Imbalance, and Microbial Shifts

According to Kim, "Our high-resolution metagenomic map shows a dramatic functional shift toward inflammation and metabolic imbalance, a loss of protective short-chain fatty acid producers, such as Faecalibacterium prausnitzii, and an overactivation of pathways, such as the urea cycle, linked to disease severity."

The findings suggest that the gut ecosystem in people with CAD undergoes significant changes that promote inflammation and disrupt normal metabolic processes. These shifts may help explain why the gut microbiome plays such a strong role in cardiovascular disease.

When "Good" Bacteria Turn Harmful

Surprisingly, the study also showed that bacteria typically seen as beneficial can sometimes become harmful. Microbes such as Akkermansia muciniphila and F. prausnitzii, often considered "friendly" species, appear to act differently depending on whether they come from a healthy or a diseased gut. This dual nature, Kim noted, highlights how context can transform even protective microbes into contributors to disease.

The results also revealed how complex it is to link specific bacteria to disease outcomes. Earlier research had reported that certain species within the family Lachnospiraceae decrease in people with CAD. Yet Kim's team found that other Lachnospiraceae species actually increase in abundance. "Lachnospiraceae may be the Dr. Jekyll and Mr. Hyde of the gut," Kim said. Some types appear beneficial, while others may worsen disease. "The big unanswered question now is which strains are the healers, and which are the troublemakers."

Toward Precision Microbial Medicine

The researchers plan to combine microbial data with genetic and metabolic information to better understand how gut microbes influence heart disease at a mechanistic level. Their long-term goal is to develop precision-based treatments that use microbial insights to prevent cardiovascular disease before it begins.

Kim emphasized that prevention is the most promising approach to lowering the global impact of heart disease. Potential strategies could include microbial therapies -- such as stool-based diagnostic screening -- or dietary interventions designed to restore beneficial bacteria or inhibit harmful pathways.

By uncovering the specific bacterial species and biological mechanisms involved, scientists are moving closer to using the gut microbiome as a powerful tool for maintaining heart health.

Read more …Scientists find 15 gut bacteria that may drive heart disease

If you’ve been following recent debates about health, you’ve been hearing a lot about vaccines[1], diet, measles, Medicaid cuts and health insurance costs[2] – but much less about one of the greatest threats to global public health[3]: climate change.

Anybody who’s fallen ill during a heat wave, struggled while breathing wildfire smoke[4] or been injured cleaning up from a hurricane[5] knows that climate change can...

Read more

Affordable health care was the primary point of contention[1] in the longest government shutdown in U.S. history, which hit 43 days on Nov. 12, 2025.

This fight highlights a persistent concern for Americans despite passage of the landmark Affordable Care Act 15 years ago.

In 2024, 27.2 million Americans, or 8.2% [2] of the population, lacked health insurance entirely. A significant number of Americans have trouble affording...

Read more

Date:
Source:
University of California - San Diego
Summary:
GLP-1 drugs such as Ozempic and Wegovy may extend the lives of colon cancer patients, according to a major UC San Diego study. Patients on the medications had less than half the mortality rate of non-users. Researchers suspect the drugs’ anti-inflammatory and metabolic effects contribute to improved outcomes. They’re now calling for clinical trials to test whether these findings reflect a true anti-cancer mechanism.

FULL STORY


Wegovy and Ozempic Tied to Lower Cancer Deaths
Drugs like Ozempic and Wegovy appear to slash colon cancer mortality by more than half in a UC San Diego study. Scientists think their impact on inflammation, insulin, and metabolism could explain the powerful effect. Credit: Shutterstock

A new study from the University of California San Diego suggests that glucagon-like peptide-1 (GLP-1) receptor agonists, a class of medications originally developed for type 2 diabetes, may have benefits that extend far beyond blood sugar and weight management. These drugs, which include semaglutide (sold as Ozempic and Wegovy) and tirzepatide (known as Mounjaro), are already well known for helping people lose weight and manage metabolic conditions. Now, researchers have discovered that they might also be linked to better survival outcomes in colon cancer patients.

The study analyzed medical records from more than 6,800 people diagnosed with colon cancer across University of California Health facilities. Patients who were taking GLP-1 medications were less than half as likely to die within five years compared to those not using the drugs (15.5% versus 37.1%). This striking difference points to a potentially powerful new use for drugs that are already transforming diabetes and obesity treatment.

The research was led by Raphael Cuomo, Ph.D., an associate professor in the Department of Anesthesiology at UC San Diego School of Medicine and a member of the UC San Diego Moores Cancer Center. His team used the University of California Health Data Warehouse to review outcomes across the state's academic medical centers.

After accounting for important factors such as age, body mass index (BMI), cancer severity, and other health conditions, the team found that people taking GLP-1 drugs still had a significantly lower risk of death. This consistency suggests the protective benefit of GLP-1 therapy may be independent of other medical or lifestyle variables.

Why GLP-1 Drugs Might Protect Against Cancer

The benefit appeared strongest in patients with obesity (BMI over 35). This finding hints that GLP-1 drugs may help offset some of the inflammation and metabolic stress that can make cancer harder to treat.

Scientists are exploring several possible explanations for this effect. GLP-1 receptor agonists are known to lower inflammation throughout the body, enhance insulin sensitivity, and promote weight loss -- all factors that can influence cancer growth and progression. Experimental studies in laboratories also indicate that GLP-1 drugs may directly inhibit the growth of tumor cells, encourage cancer cell death, and alter the surrounding environment within tumors to make them less supportive of disease spread.

However, researchers caution that it is still unclear whether the lower death rate seen in this study reflects a direct anti-cancer action or an indirect result of improved overall metabolic health.

Next Steps: Clinical Trials Needed

Dr. Cuomo emphasized that the findings are observational, meaning they do not yet prove that GLP-1 drugs directly improve cancer outcomes. These results highlight an urgent need for clinical trials to test whether GLP-1 medications can actually enhance cancer survival, particularly among patients with obesity-related cancers.

The study was published in Cancer Investigation on November 11, 2025.


Story Source:

Materials provided by University of California - San Diego. Note: Content may be edited for style and length.


Journal Reference:

  1. Raphael E. Cuomo. The Influence of GLP-1 Receptor Agonists on Five-Year Mortality in Colon Cancer Patients. Cancer Investigation, 2025; 1 DOI: 10.1080/07357907.2025.2585512[1]

Cite This Page:

University of California - San Diego. "Wegovy and Ozempic tied to dramatically lower cancer deaths." ScienceDaily. ScienceDaily, 12 November 2025. <www.sciencedaily.com/releases/2025/11/251112011810.htm>.

University of California - San Diego. (2025, November 12). Wegovy and Ozempic tied to dramatically lower cancer deaths. ScienceDaily. Retrieved November 12, 2025 from www.sciencedaily.com/releases/2025/11/251112011810.htm

University of California - San Diego. "Wegovy and Ozempic tied to dramatically lower cancer deaths." ScienceDaily. www.sciencedaily.com/releases/2025/11/251112011810.htm (accessed November 12, 2025).

RELATED STORIES


Your Pancreas May Be Making Its Own Version of Ozempic[2]

Sep. 21, 2025 — Duke University scientists have discovered that pancreatic alpha cells, long believed to only produce glucagon, actually generate powerful amounts of GLP-1 — the same hormone mimicked by popular ...

The Next Ozempic: A 4-in-1 Breakthrough for Lasting Weight Loss[3]

Sep. 1, 2025 — Scientists are racing to improve weight loss treatments beyond drugs like Ozempic and Wegovy, which are effective but plagued by nausea, bone loss, and weight regain. Tufts University chemists have ...

Fat Melts Away, but So Does Muscle: What Ozempic Users Need to Know[4]

July 30, 2025 — GLP-1 drugs like Ozempic are transforming weight loss, but a new UVA study warns they're not improving a critical measure of health: cardiorespiratory fitness. While these medications help ...

Genetic Evidence That Diabetes Drug GLP-1 Receptor Agonists Achieve Weight Loss Primarily by Reducing Fat Mass More Than Muscle[5]

Feb. 24, 2025 — Diabetes and obesity have become pressing health issues worldwide. Glucagon-like peptide-1 (GLP-1) receptor agonists, a class of medications widely used in the treatment of type 2 diabetes (T2D), ...

Boosting This Molecule Could Help Retain Muscle While Losing Fat[6]

Jan. 23, 2025 — Drugs like Ozempic, Wegovy, and Mounjaro are changing how millions lose weight, but they come with a hidden drawback: they can strip away muscle along with fat, sometimes making up nearly half of the ...

Gut Hormones Could Hold the Key to Fighting Fatty Liver Disease[7]

Oct. 7, 2024 — Fatty liver disease is a growing global health concern. Proglucagon-derived peptides (PGDPs), including glucagon, GLP-1, and GLP-2, are known to regulate lipid metabolism in the liver. However, the ...

TRENDING AT SCITECHDAILY.com[8]


New Vitamin D Strategy Cuts Second Heart Attack Risk in Half[9]

Are Our Climate Predictions Wrong? The Case of the Missing Plankton[10]

This Easy Daily Habit Could Hold Back Alzheimer’s for Years[11]

Scientists Were Wrong. Turkey’s Crust Is Tearing Apart[12]

Read more …Wegovy and Ozempic tied to dramatically lower cancer deaths

More Articles …